Avoiding downstream testing ultimately makes it cheaper for whoever is footing the bill, says Merrill H. Stewart, MD, Ochsner Health.

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

Panelists discuss how chronic neuroinflammation involves distinct mechanisms from acute relapses—including microglial ...

Alexander I. Spira, MD, PhD, of The US Oncology Network, discusses findings from the COCOON trial that show prophylactic ...

The market for artificial sweeteners has been projected to increase by almost 75% from 2025 through 2033, or from $3.11 ...

Panelists discuss how current multiple sclerosis (MS) therapies show limited effectiveness against progression, but emerging ...

A panelist discusses how a prospective study demonstrated that twice-daily use of a nasal spray significantly improved tear ...

A panelist discusses how personalized ITP care requires open conversations about testing costs, insurance coverage, and ...

Black men who were identified as sexual minorities were more receptive to long-acting injectable pre-exposure prophylaxis ...

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable ...

The Braidwood decision maintains the status quo for many patients, keeping preventive services covered by Medicaid under the ...

The Supreme Court decision in Medina v Planned Parenthood interprets the Social Security Acts Medicaid provision as not being ...